A $7 Million Startup Wants to Sell Preventive Care Memberships for $2,500 a Year

Venture capital has a type. For the last two years, that type has been membership medicine.

SONATA, a physician-led preventive care startup, announced a $7 million seed round this week led by Lux Capital, with participation from BoxGroup, Sunflower Capital, and founders from Ramp and Linear. The company sells annual memberships at $2,500 for founding members. No insurance billing. No per-visit charges. Unlimited physician access year-round.

If the pitch sounds familiar, that’s because it is. SONATA is building on the same core premise that DPC has operated on for over a decade: patients pay a recurring fee, and in return they get a real relationship with a doctor who has time for them.

The difference is what else comes in the box.

What SONATA Is Selling

Each membership includes in-home blood draws, whole-genome sequencing, DNA methylation analysis, and tracking of 140+ blood biomarkers over time. The company integrates wearable data and health records, then pairs everything with a board-certified physician who builds a personalized health plan.

CEO Sagan Schultz, who previously worked at Linear, described the gap they’re targeting. Data-only testing companies (think 23andMe-style kits) give you a report and leave you to figure out what it means. Traditional concierge medicine gives you the physician relationship but charges $25,000 or more per year. SONATA wants to sit in the middle.

“That’s the difference between a report and a relationship,” Schultz told AlleyWatch. “Care that compounds.”

The company is launching in New York, San Francisco, and Los Angeles, targeting members aged 30 to 40 who are already spending on fragmented health services: wearables, standalone lab tests, supplements, biohacking subscriptions. SONATA’s argument is that those dollars are wasted without a physician pulling everything together.

Where DPC Fits in the Picture

A typical DPC membership runs $70 to $100 per month for an individual, or roughly $840 to $1,200 per year. SONATA’s $2,500 price point is double that, and the genomics and methylation testing account for the premium.

The patient populations don’t overlap much right now. SONATA is going after young professionals in three coastal metros who want proactive health optimization. Most DPC practices serve a broader demographic, including families, chronic disease patients, and people who left insurance-based care because the 10-minute visit wasn’t working for them.

But the venture thesis underneath both models is identical. Patients will pay a monthly or annual fee for a doctor who knows them, has time for them, and doesn’t bill through insurance. Every dollar of venture funding that goes into proving that thesis makes the entire membership medicine category more credible.

The risk is that well-funded entrants like SONATA start moving downmarket. $2,500 today could become $1,500 next year if the genomics costs drop and the company chases volume. At that point, SONATA and DPC would be competing for the same patients, with one side carrying $7 million in venture capital and a product team from the tech industry.

What This Means

SONATA isn’t a DPC company. It doesn’t call itself one, and its price point and service bundle place it closer to concierge medicine than to the $75-a-month family doctor model.

But it’s playing in the same arena. Membership medicine, physician-led, no insurance middleman. The Lux Capital investment is one more signal that serious money sees this model as the future of primary care delivery. For independent DPC physicians, that’s encouraging and worth watching at the same time. More capital in the space means more patients learn what a membership practice looks like. It also means more competition from companies with deeper pockets and faster product cycles.

The DPC practices that will hold their ground are the ones that do what SONATA can’t: build deep, long-term, local relationships with patients who need a doctor they trust, not a genomics dashboard. That’s a hard thing to venture-fund your way into.